Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY:BSX)

64.14 +0.96 (+1.51%)
Streaming Delayed Price Updated: 10:36 AM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
The Great Consolidation: Q1 2026 M&A Activity Shatters Records Amid $3 Trillion Private Equity Surge
The global financial landscape underwent a seismic shift in the first quarter of 2026, as a "perfect storm" of stabilizing interest rates and technological urgency triggered a historic wave of mergers... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Teleflex Pivot: Inside the $1 Billion Share Buyback and Strategic Breakup
Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories... 
Via Finterra
Topics Economy World Trade
Boston Scientific Corp (NYSE:BSX) Offers Affordable Growth for Value-Conscious Investors ↗
Via Chartmill
Boston Scientific Corp (NYSE:BSX) Presents a Compelling Mix of Strong Fundamentals and Technical Breakout Potential ↗
Via Chartmill
News headline image
Hologic, Inc. (NASDAQ: HOLX): A New Chapter as a Women’s Health Powerhouse
Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a... 
Via Finterra
Topics Artificial Intelligence Retirement World Trade
News headline image
Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that... 
Via MarketMinute
News headline image
3 of Wall Street’s Favorite Stocks for Long-Term Investors
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
The Martha Transformation: A Deep Dive into Medtronic’s 2026 Pivot
As of April 3, 2026, Medtronic plc (NYSE: MDT) stands at a critical inflection point in its 77-year history. Once viewed as a lumbering healthcare conglomerate burdened by its own scale, the... 
Via Finterra
Topics Artificial Intelligence Initial Public Offering Product Recall
News headline image
The Great Unlocking: 2026 M&A Surge Ignites as Private Equity Confidence Hits Record 86%
NEW YORK — The global mergers and acquisitions (M&A) market has entered a period of unprecedented expansion in the first half of 2026, marking a definitive end to the "deal desert" of previous years.... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability
The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided... 
Via MarketMinute
Topics Economy Retirement
News headline image
The Great Rebound: US Megadeals Surge 319% as Corporate Consolidation Returns with a Vengeance
The first quarter of 2026 has signaled a definitive end to the "deal drought" that plagued the previous three years, as American corporations embark on an unprecedented wave of consolidation. Driven by... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Medtronic Transformation: A Deep Dive into the Future of a MedTech Titan
As of April 1, 2026, the global medical technology landscape is undergoing a profound shift, and at the center of this evolution is Medtronic plc (NYSE: MDT). Long regarded as the "sleeping giant" of... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Deep Dive: Boston Scientific (BSX) and the New Era of Medical Device Dominance
Date: March 31, 2026 Introduction Boston Scientific Corporation (NYSE: BSX) finds itself at a critical crossroads this morning. After a year of record-breaking growth and the successful launch of its... 
Via Finterra
Topics Lawsuit Product Recall
News headline image
Stocks making big moves yesterday: Avis Budget Group, Boston Scientific, CLEAR Secure, DNOW, and Comcast
Check out the companies making headlines yesterday: Avis Budget Group (NASDAQ:CAR): Car rental services provider Avis (NASDAQ:CAR) fell by 9% on Monday after... 
Via StockStory
Topics Government
News headline image
Stock Market Today, March 30: Boston Scientific Falls After Delivering Underwhelming Trial Results ↗
Today, March 30, 2026, investors send Boston Scientific shares lower as they dig deeper into the company's latest trial update. 
Via The Motley Fool
Topics Stocks
News headline image
Boston Scientific (BSX) Stock Trades Down, Here Is Why
What Happened? Shares of medical device company Boston Scientific (NYSE:BSX) fell 9.4% in the afternoon session after Raymond James downgraded the stock to O... 
Via StockStory
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
Which S&P500 stocks are the most active on Monday? ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
These S&P500 stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
The $1 Trillion Resurrection: Global M&A Hits Historic Milestone in Q1 2026 as Jefferies Eyes 'Strategic Renaissance'
The global mergers and acquisitions (M&A) market has roared back to life in the first quarter of 2026, shattering expectations and signaling a definitive end to the dealmaking drought of previous... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Why Boston Scientific's Big Dip Could Be a Bigger Opportunity ↗
Via MarketBeat
News headline image
The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips
As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Movers and shakers in today's after-hours session for S&P500 stocks? ↗
Via Chartmill
Which stocks are moving after the closing bell on Monday? ↗
Via Chartmill
News headline image
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment ↗
EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.